MedTrace Logo

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

NCT03282435 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-09-14

No results posted yet for this study

Summary

to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy

Conditions

Interventions

BIOLOGICAL

CIK cells with PD-1 blocking

CIK cellular therapy with PD-1 blocking

OTHER

standard lung cancer treament

standard non-small cell lung cancer treatment: surgery, chemotherapy

BIOLOGICAL

CIK cells without PD-1 blocking

CIK cellular therapy without PD-1 blocking

Sponsors & Collaborators

  • Dalian University

    lead OTHER

Principal Investigators

  • xiaolin Yuan · Affiliated Zhongshan Hospital of Dalian University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2023-01-31
Completion
2023-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03282435 on ClinicalTrials.gov